Literature DB >> 20728032

Radiographic findings in bisphosphonate-treated patients with stage 0 disease in the absence of bone exposure.

Matthew Hutchinson1, Felice O'Ryan, Vicente Chavez, Phenius V Lathon, Gabriela Sanchez, David C Hatcher, A Thomas Indresano, Joan C Lo.   

Abstract

PURPOSE: Radiographic features in patients with bisphosphonate-related osteonecrosis of the jaw (BRONJ) are well described, but less is known in bisphosphonate-exposed individuals with stage 0 disease (clinical symptoms without exposed necrotic bone) considered at risk for BRONJ. We sought to characterize radiographic findings in a subgroup of patients with concerning clinical symptoms and bisphosphonate exposure to identify imaging features that may presage development of BRONJ.
MATERIALS AND METHODS: A dental symptom survey was returned by 8,572 Kaiser Permanente Health Plan members receiving chronic oral bisphosphonate therapy, and 1,005 patients reporting pertinent dental symptoms or complications after dental procedures were examined. Those without BRONJ but with concerning symptoms were referred for clinical evaluation, including imaging. Among the subset who received maxillofacial imaging, we identified those with stage 0 disease and abnormal radiographic features.
RESULTS: There were a total of 30 patients without exposed bone but with concerning symptoms who received maxillofacial imaging (panoramic radiography or computed tomography) in the context of clinical care. Among these 30 patients, 10 had stage 0 disease with similar radiographic features of regional or diffuse osteosclerosis in clinically symptomatic areas, most with extension beyond the involved site. Other findings in these 10 patients included density confluence of cortical and cancellous bone, prominence of the inferior alveolar nerve canal, markedly thickened and sclerotic lamina dura, uniform periradicular radiolucencies, cortical disruption, lack of bone fill after extraction, and a persisting alveolar socket. None had exposed bone develop during 1-year follow-up. The remaining 20 patients had normal or localized radiographic findings consistent with odontogenic pathology.
CONCLUSION: In 10 of 30 symptomatic patients referred for clinical evaluation and imaging, a consistent finding was conspicuous osteosclerosis in clinically symptomatic areas characteristic of stage 0 disease. These data support the need to better understand radiographic features associated with bisphosphonate exposure and to determine whether osteosclerosis is a specific finding indicative of the risk for progression to BRONJ. Copyright 2010 American Association of Oral and Maxillofacial Surgeons. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20728032     DOI: 10.1016/j.joms.2010.05.003

Source DB:  PubMed          Journal:  J Oral Maxillofac Surg        ISSN: 0278-2391            Impact factor:   1.895


  39 in total

Review 1.  Bisphosphonate-related osteonecrosis of the jaw: from the sine qua non condition of bone exposure to a non-exposed BRONJ entity.

Authors:  Valesca Sander Koth; Maria Antonia Figueiredo; Fernanda Gonçalves Salum; Karen Cherubini
Journal:  Dentomaxillofac Radiol       Date:  2016-05-31       Impact factor: 2.419

2.  A retrospective study of digital subtraction technique to detect sclerotic changes in alveolar bone on intraoral radiographs of bisphosphonate-treated patients.

Authors:  M U Zaman; T Nakamoto; K Tanimoto
Journal:  Dentomaxillofac Radiol       Date:  2013-10-29       Impact factor: 2.419

3.  Prevalence of radiographic findings on jaws exposed to antiresorptive therapy: a meta-analysis.

Authors:  Kamile Leonardi Dutra; Letícia Fernanda Haas; Glaucia S Zimmermann; Gilberto Melo; Mariana Comparotto Minamisako; Carlos Flores-Mir; Márcio Corrêa
Journal:  Dentomaxillofac Radiol       Date:  2018-11-07       Impact factor: 2.419

4.  [Diagnostic imaging of drug-induced osteonecrosis of the jaw].

Authors:  V Hingst; M-A Weber
Journal:  Radiologe       Date:  2018-10       Impact factor: 0.635

5.  Rescue bisphosphonate treatment of alveolar bone improves extraction socket healing and reduces osteonecrosis in zoledronate-treated mice.

Authors:  Akishige Hokugo; Keiichi Kanayama; Shuting Sun; Kenzo Morinaga; Yujie Sun; QingQing Wu; Hodaka Sasaki; Hiroko Okawa; Courtney Evans; Frank H Ebetino; Mark W Lundy; Keivan Sadrerafi; Charles E McKenna; Ichiro Nishimura
Journal:  Bone       Date:  2019-03-26       Impact factor: 4.398

6.  Oncologic doses of zoledronic acid induce osteonecrosis of the jaw-like lesions in rice rats (Oryzomys palustris) with periodontitis.

Authors:  J Ignacio Aguirre; Mohammed P Akhter; Donald B Kimmel; Jennifer E Pingel; Alyssa Williams; Marda Jorgensen; Lakshmyya Kesavalu; Thomas J Wronski
Journal:  J Bone Miner Res       Date:  2012-10       Impact factor: 6.741

7.  Can dental panoramic radiographic findings serve as indicators for the development of medication-related osteonecrosis of the jaw?

Authors:  Christoph Klingelhöffer; Manja Klingelhöffer; Steffen Müller; Tobias Ettl; Ulrich Wahlmann
Journal:  Dentomaxillofac Radiol       Date:  2016-05-23       Impact factor: 2.419

8.  Meaning and Limitation of Cortical Bone Width Measurement with DentaScan in Medication-Related Osteonecrosis of the Jaws.

Authors:  Eiji Iwata; Masaya Akashi; Megumi Kishimoto; Junya Kusumoto; Takumi Hasegawa; Shungo Furudoi; Takahide Komori
Journal:  Kobe J Med Sci       Date:  2017-02-15

9.  Bisphosphonate-induced osteonecrosis of the jaw: comparison of disease extent on contrast-enhanced MR imaging, [18F] fluoride PET/CT, and conebeam CT imaging.

Authors:  R Guggenberger; D R Fischer; P Metzler; G Andreisek; D Nanz; C Jacobsen; D T Schmid
Journal:  AJNR Am J Neuroradiol       Date:  2012-12-06       Impact factor: 3.825

10.  Periapical disease and bisphosphonates induce osteonecrosis of the jaws in mice.

Authors:  Ben Kang; Simon Cheong; Thawinee Chaichanasakul; Olga Bezouglaia; Elisa Atti; Sarah M Dry; Flavia Q Pirih; Tara L Aghaloo; Sotirios Tetradis
Journal:  J Bone Miner Res       Date:  2013-07       Impact factor: 6.741

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.